The closing price of Elevation Oncology Inc (NASDAQ: ELEV) was $5.06 for the day, down -2.13% from the previous closing price of $5.17. In other words, the price has decreased by -$0.11 from its previous closing price. On the day, 1202412 shares were traded.
Ratios:
Our analysis of ELEV’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 21.22 and its Current Ratio is at 21.22. In the meantime, Its Debt-to-Equity ratio is 0.55 whereas as Long-Term Debt/Eq ratio is at 0.55.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on March 01, 2024, initiated with a Mkt Outperform rating and assigned the stock a target price of $7.
On May 30, 2023, SVB Securities Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $5 to $8.
On December 23, 2021, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $12.H.C. Wainwright initiated its Buy rating on December 23, 2021, with a $12 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELEV now has a Market Capitalization of 245.69M and an Enterprise Value of 192.72M.
Stock Price History:
Over the past 52 weeks, ELEV has reached a high of $5.89, while it has fallen to a 52-week low of $0.36. The 50-Day Moving Average of the stock is 3.72, while the 200-Day Moving Average is calculated to be 1.62.
Shares Statistics:
ELEV traded an average of 3.16M shares per day over the past three months and 1.07M shares per day over the past ten days. A total of 42.42M shares are outstanding, with a floating share count of 39.81M. Insiders hold about 18.17% of the company’s shares, while institutions hold 66.17% stake in the company. Shares short for ELEV as of Mar 15, 2024 were 4.63M with a Short Ratio of 1.47, compared to 4.01M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.51% and a Short% of Float of 10.57%.
Earnings Estimates
The firm’s stock currently is rated by 5 analysts. On average, analysts expect EPS of -$0.2 for the current quarter, with a high estimate of -$0.18 and a low estimate of -$0.23, while EPS last year was -$0.72. The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.18 and low estimates of -$0.26.
Analysts are recommending an EPS of between -$0.76 and -$0.92 for the fiscal current year, implying an average EPS of -$0.85. EPS for the following year is -$0.89, with 5 analysts recommending between -$0.62 and -$1.3.
